The Library
Drug-drug interactions between oral antiepileptics and oral anticancer drugs: implications to clinicians
Tools
Tools
Tools
Cheung, Yin Ting, Yap, Kevin Yi-Lwern, Chui, Wai Keung and Chan, Alexandre (2010) Drug-drug interactions between oral antiepileptics and oral anticancer drugs: implications to clinicians. European Neurology, Vol.64 (No.2). pp. 88-94. doi:10.1159/000315031 ISSN 0014-3022.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1159/000315031
Abstract
Background: Existing research has suggested that there can be potential drug-drug interaction (DDI) between antiepileptic drugs (AED) and anticancer drugs (ACD). However, information on the prevalence of patients on concurrent oral AED and oral ACD is limited. Methods: A retrospective study was conducted at the National Cancer Centre Singapore. Prevalence was calculated by identifying prescriptions with both oral AED and oral ACD from the outpatient prescription database over three years. Prevalence and physicians’ prescribing patterns were evaluated. Co-prescription was defined as medications that were prescribed by the same physician on the same day. Potentially interacting combinations were further detected using an existing database, OncoRx (www.onco-informatics.com). Results: 42,810 prescriptions that contained at least one oral ACD were identified from the database. The number and prevalence of prescriptions that had a combination of oral ACD and AED were 274 and 0.64%, respectively, with the majority (82.8%) of the AED-oral ACD pairs being co-prescribed. Per patient, the average number of exposure days to the AED-oral ACD pair was 19.5 days annually. Fifty-one (18.6%) prescriptions were identified as containing potentially interacting AED-oral ACD pairs. Discussion: There is a relatively low prevalence of AED-oral ACD combined exposure in the population we sampled; however, the combined exposure is long enough to produce clinically important DDI effects.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
||||
| Divisions: | Faculty of Science, Engineering and Medicine > Engineering > WMG (Formerly the Warwick Manufacturing Group) | ||||
| Journal or Publication Title: | European Neurology | ||||
| Publisher: | S. Karger AG | ||||
| ISSN: | 0014-3022 | ||||
| Official Date: | August 2010 | ||||
| Dates: |
|
||||
| Volume: | Vol.64 | ||||
| Number: | No.2 | ||||
| Number of Pages: | 7 | ||||
| Page Range: | pp. 88-94 | ||||
| DOI: | 10.1159/000315031 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Faculty of Science, National University of Singapore , Department of Pharmacy, National University of Singapore | ||||
| Grant number: | R-148-000-108-133 (FoS, NUoS) |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
